Eszopiclone (Lunesta) Is Not Injectable: How This Oral Sleep Medication Actually Works

Why There Is No Eszopiclone Injection

Eszopiclone exists in one pharmaceutical form: an oral tablet. The FDA-approved prescribing information lists no parenteral (injectable) formulation, and no manufacturer has developed one. The drug was designed for oral bioavailability from the start, with approximately 80% absorption through the gastrointestinal tract [1].

Some sleep medications do have injectable versions. Midazolam, for instance, is available in both oral and injectable forms for procedural sedation. Eszopiclone is not one of them. The cyclopyrrolone chemical structure of eszopiclone was optimized for oral absorption and hepatic metabolism via CYP3A4 and CYP2E1 enzymes [2]. No clinical trial has ever tested an injectable eszopiclone formulation, and the National Library of Medicine drug record confirms its single-route designation.

If you encountered claims about injecting Lunesta, those claims have no basis in pharmacology or FDA labeling. Attempting to dissolve and inject oral tablets is dangerous. Tablet excipients (binders, fillers, coatings) are not sterile, not filtered for particulates, and can cause vascular occlusion, infection, or tissue necrosis.

How Eszopiclone Actually Works: Mechanism of Action

Eszopiclone binds to GABA-A receptors in the brain, but it does so differently than benzodiazepines. It targets the alpha-1 subunit of the GABA-A receptor complex with high affinity, which mediates sedation, while showing lower affinity for the alpha-2 and alpha-3 subunits responsible for anxiolytic and muscle-relaxant effects [3].

This selectivity matters clinically. Benzodiazepines bind broadly across all GABA-A receptor subtypes, producing sedation alongside muscle relaxation, anterograde amnesia, and higher rebound insomnia risk. Eszopiclone's narrower binding profile produces sleep without as much next-day cognitive impairment at recommended doses, though the 3 mg dose can still cause measurable morning drowsiness [1].

The drug reaches peak plasma concentration (Tmax) in roughly 1 hour after oral ingestion. Its 6-hour terminal half-life makes it useful for both sleep-onset and sleep-maintenance insomnia. A high-fat meal delays absorption by approximately 1 hour, which is why the label specifies taking eszopiclone immediately before bedtime and not with or immediately after a heavy meal [1].

Eszopiclone is the S-enantiomer of zopiclone, a racemic mixture used in Europe and Canada since the 1980s. Isolating the S-enantiomer roughly doubled the potency at the GABA-A receptor compared to racemic zopiclone, allowing lower absolute doses [4]. The European Medicines Agency zopiclone assessment and subsequent pharmacokinetic studies confirmed that the R-enantiomer contributed minimally to hypnotic effect but added to side effects, particularly the bitter metallic taste that remains eszopiclone's most common adverse event (reported by up to 34% of patients on 3 mg) [1].

Proper Oral Administration of Eszopiclone

The correct way to take eszopiclone is straightforward. Swallow the tablet whole with water, immediately before getting into bed, when you can dedicate 7 to 8 hours to sleep. Do not crush, chew, or split the tablet.

Starting doses per the FDA label:

• Adults: 1 mg at bedtime. May increase to 2 mg or 3 mg if clinically needed.
• Older adults (age 65+): 1 mg at bedtime. Increase to 2 mg with caution. The 3 mg dose is not recommended in this population.
• Severe hepatic impairment: maximum 2 mg.
• Patients on strong CYP3A4 inhibitors (ketoconazole, clarithromycin): maximum 2 mg.

The FDA lowered the recommended starting dose from 2 mg to 1 mg in 2014 after post-marketing data showed next-morning impairment, particularly in women who metabolize the drug more slowly [5]. This mirrors the similar dose reduction the FDA applied to zolpidem (Ambien) in 2013.

Three rules govern timing. First, take it only when you can commit to a full night of sleep. Taking eszopiclone and then trying to stay awake increases the risk of complex sleep behaviors (sleepwalking, sleep-driving) [1]. Second, avoid alcohol entirely on nights you take eszopiclone; the combination produces additive CNS depression. Third, do not take it with or right after a high-fat meal, as fat delays absorption enough to reduce initial sleep-onset benefit.

Clinical Evidence: The Krystal 6-Month Trial

The landmark study for eszopiclone's long-term efficacy is the Krystal et al. 2003 trial published in Sleep, a 6-month, double-blind, placebo-controlled study (N=788) that established eszopiclone as the first FDA-approved hypnotic with data supporting nightly use beyond 35 days [6].

Patients received eszopiclone 3 mg or placebo nightly for 6 months. Results showed that eszopiclone reduced subjective sleep-onset latency by a mean of 25.1 minutes compared to 13.8 minutes for placebo (P<0.001). Total sleep time increased by 52.0 minutes versus 30.4 minutes for placebo. Patient-reported sleep quality improved significantly at every monthly assessment through month 6, with no evidence of tolerance development [6].

That last finding broke new ground. Prior hypnotic trials rarely extended beyond 4 to 6 weeks, partly because of regulatory concern about tolerance. The Krystal data showed no loss of efficacy over 6 months, and discontinuation after 6 months did not produce rebound insomnia on the first night of withdrawal [6]. This changed how prescribers and the FDA approached chronic insomnia treatment.

A subsequent 12-month open-label extension (N=471) confirmed sustained efficacy and tolerability [7]. The American Academy of Sleep Medicine (AASM) 2017 clinical practice guideline cited this evidence base when recommending eszopiclone as a treatment option for sleep-maintenance insomnia in adults, giving it a "WEAK" recommendation based on moderate-quality evidence [8].

Dr. Andrew Krystal, the lead investigator, stated in the original 2003 publication: "These data support the safety and sustained efficacy of eszopiclone 3 mg for the 6-month nightly treatment of primary insomnia, with no evidence of tolerance" [6].

Side Effects and Safety Considerations

The most common adverse event is dysgeusia, an unpleasant metallic or bitter taste, reported by 17% of patients on 2 mg and 34% on 3 mg in controlled trials [1]. This side effect is dose-dependent and appears related to eszopiclone's excretion in saliva.

Other frequently reported side effects at the 3 mg dose include headache (21%), somnolence (10%), dizziness (7%), and dry mouth (7%) [1]. These rates come from pooled Phase III data submitted to the FDA.

The 2019 FDA boxed warning update applied to all "Z-drugs" (eszopiclone, zolpidem, zaleplon) after 66 cases of serious injuries, including falls, burns, near-drowning, and vehicular crashes during complex sleep behaviors. Five fatalities were reported. The warning states that eszopiclone should be discontinued permanently if a patient experiences a complex sleep behavior episode [9].

Dr. Ellis Unger, then acting director of FDA's Office of Drug Evaluation I, noted: "We want healthcare professionals and patients to be aware that these common insomnia medications can cause serious injuries from complex sleep behaviors" [9].

Dependence risk exists but is lower than with benzodiazepines. As a Schedule IV controlled substance, eszopiclone carries abuse potential, particularly in patients with histories of substance use disorders. The prescribing information advises prescribers to evaluate for comorbid psychiatric conditions and to use the lowest effective dose for the shortest duration consistent with clinical need [1].

How Eszopiclone Compares to Other Insomnia Medications

Eszopiclone occupies a specific niche among insomnia treatments. Unlike zolpidem (Ambien), which has a short half-life of 2.5 hours and primarily targets sleep onset, eszopiclone's 6-hour half-life addresses both sleep onset and nighttime awakenings [10].

Compared to suvorexant (Belsomra) and lemborexant (Dayvigo), the dual orexin receptor antagonists (DORAs), eszopiclone works through a completely different mechanism. DORAs block wake-promoting orexin signaling rather than enhancing inhibitory GABA signaling. A 2020 network meta-analysis published in The Lancet (N=36,533 across 154 trials) found eszopiclone, lemborexant, and zolpidem to be the most effective agents for subjective sleep outcomes at licensed doses, while DORAs showed advantages in objective polysomnographic measures [11].

Cognitive behavioral therapy for insomnia (CBT-I) remains the AASM-recommended first-line treatment for chronic insomnia. Pharmacotherapy, including eszopiclone, is appropriate when CBT-I is unavailable, insufficient, or when the patient needs immediate symptomatic relief while behavioral interventions take effect (typically 4 to 8 sessions) [8].

Drug Interactions That Affect Eszopiclone Dosing

CYP3A4 is the primary metabolic pathway. Strong CYP3A4 inhibitors raise eszopiclone plasma levels substantially, requiring dose reduction to a maximum of 2 mg [1].

Clinically significant inhibitors include ketoconazole, itraconazole, clarithromycin, nefazodone, and ritonavir. In a pharmacokinetic study, co-administration with ketoconazole 400 mg increased eszopiclone AUC by 2.2-fold [12]. Conversely, strong CYP3A4 inducers like rifampin reduce eszopiclone exposure and may decrease efficacy. The FDA label does not recommend dose adjustment for inducers but notes the possibility of reduced effect [1].

Alcohol potentiates CNS depression additively. A pharmacodynamic study showed that eszopiclone 3 mg combined with ethanol 0.7 g/kg produced significantly greater psychomotor impairment than either substance alone [1]. The combination is contraindicated.

Concurrent use with opioids increases the risk of respiratory depression, profound sedation, coma, and death. The FDA's 2016 opioid-CNS depressant interaction warning applies to eszopiclone and all sedative-hypnotics [13].

Special Populations: Who Needs Adjusted Dosing

Older adults: Age-related decreases in hepatic function and increased receptor sensitivity lead to higher drug exposure. The AASM 2017 guideline specifically flags the fall risk associated with hypnotics in adults over 65 [8]. Start at 1 mg. Do not exceed 2 mg.

Hepatic impairment: Patients with severe liver disease (Child-Pugh Class C) showed increased eszopiclone half-life and exposure. Maximum dose is 2 mg [1].

Renal impairment: No dose adjustment is required. Less than 10% of eszopiclone is excreted unchanged in urine, and a study in patients with severe renal impairment showed no clinically meaningful change in pharmacokinetics [1].

Pregnancy: Eszopiclone is not recommended during pregnancy. Animal reproduction studies at doses 800 times the human dose showed decreased pup survival and developmental delays. No adequate human studies exist [1]. The National Library of Medicine LactMed database notes insufficient data on eszopiclone in breast milk, though the related compound zopiclone is excreted in breast milk at low levels [14].

The recommended starting dose across all populations is 1 mg, taken immediately before bedtime, with 7 to 8 hours available for sleep.